Description
1. Description
SITADOL 50 TABLETS contains Sitagliptin 50 mg, an oral antidiabetic medicine belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is used alongside diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus. Sitagliptin helps regulate glucose-dependent insulin release and reduces the secretion of glucagon when blood glucose levels are elevated.
The formulation may be prescribed alone or in combination with other diabetes medicines when clinically appropriate. Its role is to support individualized glycaemic management, with regular blood glucose monitoring, dietary planning and physical activity remaining important parts of diabetes care.
Cardiancare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Businesses searching for a Sitagliptin 50 mg tablets manufacturer India can enquire about product availability, approved specifications, manufacturing details and applicable quality documentation.
For pharmaceutical procurement teams evaluating a Sitagliptin 50 mg tablets manufacturer and supplier India, important considerations include product authorization, composition accuracy, packaging, batch traceability, shelf life and commercial supply terms.
2. Key Ingredient
Composition: Sitagliptin 50 mg
Sitagliptin is an oral antidiabetic agent classified as a DPP-4 inhibitor. It works by slowing the breakdown of incretin hormones, which help the body regulate blood glucose after meals.
By prolonging the activity of these hormones, sitagliptin enhances glucose-dependent insulin secretion and reduces glucagon secretion when glucose levels are elevated. This supports blood glucose regulation without directly stimulating insulin release regardless of glucose levels.
For businesses researching a Sitagliptin 50 mg pharmaceutical company India, procurement assessments should cover product composition, manufacturing source, approved labelling, quality assurance and applicable regulatory requirements.
Companies seeking a Sitagliptin 50 mg medicine manufacturer India should verify the manufacturing facility’s regulatory status, product authorization, batch documentation and relevant quality standards before entering into a supply arrangement.
3. Key Benefits
Blood glucose management: Helps improve glycaemic control in adults with type 2 diabetes when prescribed appropriately.
Glucose-dependent action: Supports insulin secretion primarily when blood glucose levels are elevated.
Glucagon regulation: Helps reduce excessive glucagon secretion in a glucose-dependent manner.
Oral administration: Offers a convenient tablet-based treatment option for eligible patients.
Combination therapy option: May be used with selected antidiabetic medicines under medical supervision.
Complementary treatment approach: Can support a comprehensive diabetes management plan that includes diet, exercise and monitoring.
The clinical response depends on the patient’s condition, kidney function, other medicines and adherence to the prescribed treatment plan.
Pharmaceutical buyers searching for a Sitagliptin 50 mg supplier India should verify product authenticity, availability, documentation, shelf life and supply continuity.
An Sitagliptin 50 mg tablet wholesaler and distributor India enquiry may include stock availability, minimum order quantities, delivery coverage, licensing requirements and applicable commercial terms.
Businesses seeking a Sitagliptin 50 mg bulk supplier India should request a formal quotation and confirm batch traceability, packaging specifications, storage requirements and quality documentation.
A Sitagliptin 50 mg pharmaceutical distributor India should verify distribution eligibility, product availability and approved promotional information before beginning commercial activities.
4. How Does It Work?
Sitagliptin selectively inhibits the DPP-4 enzyme, which normally breaks down incretin hormones such as GLP-1 and GIP.
By slowing the breakdown of these hormones, sitagliptin helps increase glucose-dependent insulin secretion and decrease glucagon secretion when blood glucose is elevated. These actions support better regulation of blood glucose levels.
Because its effect on insulin secretion is glucose-dependent, sitagliptin generally has a lower risk of hypoglycaemia when used alone than medicines that directly stimulate insulin secretion. However, the risk can increase when it is combined with insulin or sulfonylureas.
5. Directions for Use
Dosage: Take only as prescribed by a doctor. The appropriate dose depends on the patient’s clinical condition and kidney function.
Administration: Sitagliptin may generally be taken with or without food, according to the approved product information.
Regular timing: Follow the prescribed schedule consistently and avoid changing the dose without medical advice.
Kidney function: Dose adjustment may be necessary in patients with moderate or severe renal impairment or end-stage kidney disease.
Treatment adherence: Continue recommended dietary measures, physical activity and blood glucose monitoring.
Missed dose: Follow the doctor’s or pharmacist’s advice. Do not take a double dose to compensate for a missed dose.
A 50 mg strength is not the appropriate dose for every patient. The prescriber must determine the suitable regimen according to the patient’s kidney function and overall treatment plan.
6. Possible Side Effects
Possible adverse effects include:
Nasopharyngitis or common cold-like symptoms
Headache
Upper respiratory tract symptoms
Gastrointestinal discomfort in some patients
Important but less common adverse reactions can include:
Pancreatitis: Persistent severe abdominal pain, particularly if it radiates to the back, requires urgent medical assessment.
Hypoglycaemia: Risk increases when sitagliptin is combined with insulin or sulfonylureas.
Hypersensitivity: Serious allergic reactions, including angioedema or anaphylaxis, require emergency care.
Severe joint pain: New or severe joint pain should be reported to a healthcare professional.
Bullous pemphigoid: Rare blistering skin reactions have been reported.
Heart failure considerations: Patients with a history of heart failure should discuss treatment suitability with their doctor.
This list is not exhaustive. Seek professional medical advice about persistent or concerning symptoms.
7. Safety Information
Medical supervision: Use only under the guidance of a qualified healthcare professional.
Contraindications: Do not use in patients with known serious hypersensitivity to sitagliptin or any component of the formulation.
Kidney health: Assess renal function before and during treatment as clinically indicated. Dose adjustment is required in moderate or severe renal impairment.
Pancreatic health: Use caution in patients with a history of pancreatitis. Seek urgent assessment if symptoms suggest acute pancreatitis.
Pregnancy and breastfeeding: Consult a doctor before use during pregnancy, when planning pregnancy or while breastfeeding. The clinician should assess appropriate diabetes treatment.
Drug interactions: Inform the doctor about all prescription medicines, over-the-counter products and supplements, particularly insulin and sulfonylureas.
Heart failure: Discuss a history of heart failure or significant cardiac disease with the prescribing clinician.
Storage: Store in the original packaging according to the approved product label, protected from excessive heat and moisture and out of reach of children.
This information is educational and does not replace approved prescribing information or individualized medical advice.
8. B2B Pharmaceutical Business Enquiries
Cardiancare focuses on cardiac and diabetic healthcare and provides a contact point for pharmaceutical trade enquiries. Distributors, wholesalers and eligible business partners should confirm current product availability and commercial arrangements directly with the company.
Businesses researching a Sitagliptin 50 mg PCD pharma franchise India opportunity can enquire about eligible products, territory availability, partner requirements and applicable commercial terms.
For a Sitagliptin 50 mg tablets PCD pharma franchise enquiry, prospective partners can request details about product availability, minimum order requirements, promotional support, distribution eligibility and relevant documentation.
Companies exploring a Sitagliptin 50 mg tablet PCD franchise should verify whether the formulation is available under the current programme before making investment or promotional commitments.
Businesses evaluating Sitagliptin 50 mg third party manufacturing India services should first confirm whether the proposed company offers these arrangements. Relevant checks include manufacturing permissions, product approvals, applicable GMP compliance, minimum batch quantities and quality documentation.
A Sitagliptin 50 mg tablet third party manufacturer India enquiry should cover the manufacturing facility’s regulatory status, quality systems, batch release procedures, packaging specifications and contractual responsibilities.
Companies investigating Sitagliptin 50 mg contract manufacturing India should discuss formulation specifications, technical documentation, quality agreements, regulatory responsibilities, manufacturing authorization and commercial feasibility with the proposed manufacturing partner.
B2B call to action: Contact Cardiancare through its official website to enquire about current product availability, pharmaceutical distribution opportunities and applicable business arrangements. Franchise and manufacturing services require direct confirmation before being advertised as available.For more information about SITADOL 50 TABLETS (Sitagliptin 50 mg), Click Here: [Insert Product Page URL]
Reviews
There are no reviews yet.